Biotech Stars And Startups Raise $168m In Venture Cash
This article was originally published in Scrip
Executive Summary
Drug developers continue to raise significant venture capital in 2015 with experienced executives and novel therapeutic approaches attracting large VC funding rounds to support early-stage research and development programs, including a $40m Series C round for True North Therapeutics.
You may also be interested in...
Finance Watch: Bicycle Spins Toward Clinic With $52m Round; Stock Spikes Spur Offerings
Bicycle closes a $52m Series B to test its bicyclic peptides in humans, while Decipera, Harpoon and TP Therapeutics also top a $263m list of recent venture capital deals. In public company financings, Alnylam, Aerie and others price offerings to raise cash while their stocks are on the rise.
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth
Third Rock closed a $616m venture capital fund, exceeding the firm’s goal of $600m to fund newly formed biopharma companies, following Sofinnova and others with new VC and debt funds for early- to mid-stage life science companies. Also, five drug developers raised $256m in new VC cash.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.